Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Common Equity (2019 - 2026)

ADC Therapeutics has reported Common Equity over the past 8 years, most recently at -$216.4 million for Q1 2026.

  • Quarterly results put Common Equity at -$216.4 million for Q1 2026, up 9.17% from a year ago — trailing twelve months through Mar 2026 was -$216.4 million (up 9.17% YoY), and the annual figure for FY2025 was -$185.8 million, up 8.29%.
  • Common Equity reached -$216.4 million in Q1 2026 per ADCT's latest filing, down from -$185.8 million in the prior quarter.
  • Across five years, Common Equity topped out at $162.7 million in Q1 2022 and bottomed at -$238.2 million in Q1 2025.
  • Median Common Equity over the past 5 years was -$148.2 million (2023), compared with a mean of -$89.4 million.
  • The largest annual shift saw Common Equity plummeted 784.15% in 2024 before it grew 9.17% in 2026.
  • Over 5 years, Common Equity stood at $79.5 million in 2022, then tumbled by 286.59% to -$148.2 million in 2023, then tumbled by 36.69% to -$202.6 million in 2024, then grew by 8.29% to -$185.8 million in 2025, then dropped by 16.44% to -$216.4 million in 2026.
  • Business Quant data shows Common Equity for ADCT at -$216.4 million in Q1 2026, -$185.8 million in Q4 2025, and -$238.2 million in Q3 2025.